Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY25 results · Apr–Jun 2024
Gufic Biosciences reported revenue from operations of ₹202.81 crore and net profit of ₹20.86 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 202.81 | — | — | 194.99 | +4.0% |
| Other income | 1.25 | — | — | 0.88 | +42.3% |
| Total income | 204.07 | — | — | 195.87 | +4.2% |
| Profit before tax | 28.10 | — | — | 27.12 | +3.6% |
| Net profit for the period | 20.86 | — | — | 20.05 | +4.0% |
| EPS, basic (₹) | 2.08 | — | — | 2.00 | +4.0% |
| Net margin (%) | 10.3 | — | 10.3 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 202.81 | 195.02 | +4.0% | 194.99 | +4.0% |
| Other income | 1.25 | 0.88 | +42.4% | 0.88 | +42.3% |
| Total income | 204.07 | 195.90 | +4.2% | 195.87 | +4.2% |
| Profit before tax | 28.11 | 28.05 | +0.2% | 27.12 | +3.6% |
| Net profit for the period | 20.86 | 20.62 | +1.1% | 20.05 | +4.1% |
| EPS, basic (₹) | 2.08 | 2.13 | −2.3% | 2.00 | +4.0% |
| Net margin (%) | 10.3 | 10.6 | 10.3 |
Consolidated
- Filed with BSE
- 29 Aug 2024, 16:37 IST
- Board meeting
- 14 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Aug 2024, 16:37 IST
- Board meeting
- 14 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE